| **Variable** | **Standard**, N = 4,1221 | **ACE-inhibitor therapy**, N = 4,1451 | **p-value**2 |
| --- | --- | --- | --- |
| **Age Group** |  |  | 0.2 |
| ≤ 65 | 2,292 (56%) | 2,250 (54%) |  |
| > 65 | 1,830 (44%) | 1,895 (46%) |  |
| **Systolic Blood Pressure** | 133 (17) | 134 (17) | 0.2 |
| **Gender** |  |  | 0.021 |
| Male | 3,422 (83%) | 3,359 (81%) |  |
| Female | 700 (17%) | 786 (19%) |  |
| **History of Diabetes** |  |  | 0.081 |
| No Diabetes | 3,466 (84%) | 3,425 (83%) |  |
| Diabetes | 656 (16%) | 720 (17%) |  |
| **History of Hypertension** |  |  | 0.7 |
| No Hypertension | 2,258 (55%) | 2,253 (54%) |  |
| Hypertension | 1,864 (45%) | 1,892 (46%) |  |
| 1n (%); Mean (SD) | | | |
| 2Pearson's Chi-squared test; Welch Two Sample t-test | | | |